Substance / Medication

Pyrilamine

Overview

Active Ingredient
pyrilamine
RxNorm CUI
9009

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Naproxen, paracetamol and pamabrom versus paracetamol, pyrilamine and pamabrom in primary dysmenorrhea: a randomized, double-blind clinical trial.
Ortiz Mario I, Murguía-Cánovas Gabriela, Vargas-López Laura C et al. · Medwave · 2016
PMID: 27813503Observational
Sex differences in mouse behavior following pyrilamine treatment: role of histamine 1 receptors in arousal.
Easton A, Norton J, Goodwillie A et al. · Pharmacol Biochem Behav · 2004
PMID: 15582029Observational
Influence of histamine, cimetidine and pyrilamine on naloxone-induced jumping in morphine-dependent mice.
Zarrindast Mohammad Reza, Assadi Elham, Oryan Shahrbano et al. · Eur J Pharmacol · 2003
PMID: 12818697Observational
Pyrilamine-induced prolonged QT interval in adolescent with drug overdose.
Paudel Govinda, Syed Muhammad, Kalantre Sarika et al. · Pediatr Emerg Care · 2011
PMID: 21975494Case Report
[Research progress of pyrilamine-sensitive H~+/OC antiporter].
Wang Xin-yi, Zhang Zhi-rong · Yao Xue Xue Bao · 2016
PMID: 29878742Review
Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors.
Hiranaka Seiya, Tega Yuma, Higuchi Kei et al. · ACS Med Chem Lett · 2018
PMID: 30258535OtherFull text (PMC)
Involvement of proton-coupled SLC49A4-mediated transport in the export of lysosomally trapped pyrilamine.
Akino Shogo, Yasujima Tomoya, Shibutani Rei et al. · Drug Metab Dispos · 2023
PMID: 37963658Preclinical
Pyrilamine-sensitive proton-coupled organic cation (H/OC) antiporter for brain-specific drug delivery.
Wang Xinyi, Qi Bowen, Su Huifang et al. · J Control Release · 2017
PMID: 28351667Preclinical
Pyrilamine inhibits nicotine-induced catecholamine secretion.
Kim Dong-Chan, Yun So Jeong, Park Yong-Soo et al. · Neurochem Int · 2014
PMID: 24813183Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mepyramine (substance)
SNOMED CT
387087002
UMLS CUI
C0034282
RxNorm CUI
9009

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.